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ARTICLE
FBXO32 promotes microenvironment underlying
epithelial-mesenchymal transition via CtBP1 during
tumour metastasis and brain development
Sanjeeb Kumar Sahu1, Neha Tiwari2, Abhijeet Pataskar1, Yuan Zhuang1, Marina Borisova1, Mustafa Diken3,
Susanne Strand4, Petra Beli1 & Vijay K. Tiwari1
The set of events that convert adherent epithelial cells into migratory cells are collectively
known as epithelial–mesenchymal transition (EMT). EMT is involved during development, for
example, in triggering neural crest migration, and in pathogenesis such as metastasis. Here
we discover FBXO32, an E3 ubiquitin ligase, to be critical for hallmark gene expression and
phenotypic changes underlying EMT. Interestingly, FBXO32 directly ubiquitinates CtBP1,
which is required for its stability and nuclear retention. This is essential for epigenetic
remodeling and transcriptional induction of CtBP1 target genes, which create a suitable
microenvironment for EMT progression. FBXO32 is also ampliﬁed in metastatic cancers and
its depletion in a NSG mouse xenograft model inhibits tumor growth and metastasis. In
addition, FBXO32 is essential for neuronal EMT during brain development. Together, these
ﬁndings establish that FBXO32 acts as an upstream regulator of EMT by governing the gene
expression program underlying this process during development and disease.
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Epithelial cells remain in close contact with their neighborsand maintain an apical–basal axis of polarity by thesequential arrangement of adherent junctions, desmosomes,
and tight junctions1. Following the induction of epithelial to
mesenchymal transition (EMT) program, cells undergo molecular
and phenotypic remodeling that involves changes like cytoskeletal
reorganization and loss of cell–cell junctions. This allows epi-
thelial cells to escape from their original location by acquiring a
migratory, mesenchymal identity2. Such a dramatic change in cell
fate is essential for key processes during embryonic development,
such as embryo implantation, embryonic layer formation, gas-
trulation and neural tube formation. In adults, this change in cell
b c
0
50
100
NMuMG
m
R
N
A
(no
rm
ali
ze
d t
o C
tcf
)
**
**
*
RNA-seq EMT timecourse (NMuMG)
Analysis of differentially expressed genes
Investigation of genes induced during EMT
based on: literature, localization, tumor datasets
Expression validation in other EMT models: 
primary human HMEC cells, EpRAS, Neuronal EMT,
Invasive/ non-invasive cancer cell lines
Phenotype and molecular characterization
upon depletion of candidate genes during EMT Un
tre
at
ed d1 d4 d7
TGF-β
Un
tre
ar
te
d
si
Co
nt
ro
l
d4
 T
G
F-
β
si
Fb
xo
32
-1
d4
 T
G
F-
β
NMuMG
0
5
10
15
m
R
N
A
(no
rm
ali
ze
d t
o C
TC
F)
HMEC
***
Un
tre
at
ed d1 d4 d7
TGF-β
NMuMG
Cdh1 Cdh2 Fn1 Snai1 Zeb2
si
Fb
xo
32
-2
d4
 T
G
F-
β
m
R
N
A 
(no
rm
ali
ze
d t
o C
tcf
)
Fbxo32
Untreated
d4 TGF-β siControl
d4 TGF-β siFbxo32-1
d4 TGF-β siFbxo32-2
HMEC 
CL
DN
3
CD
H2 FN
1
TW
IST
2
SN
AI1
SN
AI2 ZE
B1
m
R
N
A 
(no
rm
ali
ze
d t
o C
TC
F)
0
0.01
0.02
0.2
0.4
100
200
Untreated
d4 TGF-β siControl
d4 TGF-β siFBXO32-1
d4 TGF-β siFBXO32-2
0
500
1000
1500
2000
FB
XO
32
***
***
Bright fieldE-cadherin N-cadherin FibronectinPhalloidinZO-1 Paxillin
0
0.2
0.4
0.6
0.8
**
**
0
5
10
15
20
*
**
0
2
4
6
*
*
0
5
10
15
20
*
*
0
0.01
0.02
0.03
0.04
**
**
0
0.05
0.10
0.15
0.20
*
**
Twist1
0
0.005
0.010
0.015
0.020 **
**
**
**
**
**
**
**
**
*
**
*
**
**
**
*
**
**
Un
tre
at
ed
d1 d4 d7
TGF-β
FBXO32
42 kDa
Lamin-B1
68 kDa
NMuMG
Un
tre
at
ed
d1 d4 d7
HMEC
FBXO32
42 kDa
β-actin
42 kDa
TGF-β
d
e
46 kDa
46 kDa
80 kDa
32 kDa
a
f
g h
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01366-x
2 NATURE COMMUNICATIONS |8:  1523 |DOI: 10.1038/s41467-017-01366-x |www.nature.com/naturecommunications
fate is important for processes like tissue regeneration and wound
healing1–4. However, aberrant activation of the EMT program is
associated with disease phenotypes such as organ ﬁbrosis5 and
tumor metastasis4, 6.
A number of signaling pathways, such as TGF-β, FGF, EGF,
HGF, Wnt/β-catenin and Notch are known to induce EMT1, 7.
Among these, TGF-β is known to be the most potent and a
prototypic inducer of EMT in various contexts, including devel-
opment and cancer metastasis, whereas the others have more
context-speciﬁc functions2, 8. A large number of evidences have
established that the microenvironment plays a critical role during
initiation and progression of EMT9. However, the effectors,
through which TGF-β mediates remodeling of the micro-
environment to promote EMT, remain poorly explored. It is also
well established that EMT relies on deﬁned, genome-wide tran-
scriptional reprogramming10, 11. A number of transcription fac-
tors are implicated in this process, including SNAIL, ZEB, and
several basic helix-loop-helix proteins8, 10, 12. Importantly, these
transcription factors modulate gene expression in partnership
with co-regulator proteins such as CTBPs13–15. Several studies
have reported that CtBPs form complexes with a variety of epi-
genetic regulators or corepressor complexes that recruit epige-
netic regulators13, 15, 16. CtBPs are also known to undergo
dynamic posttranslational modiﬁcations which inﬂuence their
stability or subcellular localization14. Recent studies have sug-
gested dispensability of the established key EMT transcription
factors in driving metastasis and further vouched for a need of
exploring more potent factors driving this process17–19.
Advances in proteomics have begun to highlight the role of
post-translational modiﬁcations during EMT and their enormous
complexity and regulatory potential8, 20. Ubiquitination via the
ubiquitin–proteasome system governs diverse cellular processes,
such as cell proliferation, cell cycle progression, transcription and
apoptosis21. F-box proteins, the substrate-recognition subunits of
Skp1–Cullin1–F-box protein E3 ligase complex, play pivotal roles
in ubiquitination and subsequent activation or degradation of
target proteins, depending on the lysine residue of ubiquitin (Ub)
that participates in the formation of poly-Ub chains22, 23. Recent
studies have shed light on the biological functions attributed by
these F-box proteins24. FBXO32 (also known as Mafbx/Atrogin1)
was ﬁrst identiﬁed as a muscle-speciﬁc F-box protein, and further
studies indicated its importance during heart development and
muscle homeostasis25, 26. This protein is also induced upon stress,
for instance, during serum starvation and hypoxia, and it func-
tions as an apoptosis regulator27, 28. In a previous study, FBXO32
promoter was shown to be repressed by DNA methylation in
ovarian cancer and its expression was correlated with shorter
progression-free survival29. FBXO32 has been implicated in the
regulation of transcription factor stability (e.g., Myc) and locali-
zation (e.g., Foxo1 and Foxo3a)26, 30. A very recent study showed
an association between EMT and Fbxo32 in tumors with acquired
platinum resistance31. However, despite these advances and
indications of its role in cancer, the function of FBXO32 in EMT
progression, metastasis and its contributions to the gene reg-
ulatory circuitry underlying these processes remain completely
unknown.
Here we discover FBXO32 to be required in various contexts of
EMT, including in disease and development. We report that
FBXO32 is substantially induced during EMT and plays a critical
role in the transition towards mesenchymal identity by governing
the required gene expression program. We show that FBXO32-
dependent K63-linked ubiquitination of CtBP1 is required for its
nuclear retention, which is essential for mediating transcriptional
changes via epigenetic reprogramming of EMT target genes.
These include various chemokines, chemokine receptors, and
matrix metalloproteinases, thus promoting a suitable environ-
ment promoting EMT progression. FBXO32 is also highly
ampliﬁed in a large panel of cancers, and its depletion severely
impairs the metastatic properties of cancer cells both in vitro and
in vivo. Furthermore, depletion of FBXO32 during brain devel-
opment impairs neuronal EMT. Together, these observations
establish FBXO32 among the most potent regulator of EMT by
governing the gene expression program that underlies this pro-
cess during both development and disease.
Results
FBXO32 is essential for epithelial–mesenchymal transition. To
identify so far unknown regulators of EMT, we employed an
established model system in which normal murine mammary
gland epithelial cells (NMuMG) undergo TGF-β-induced EMT
with high synchrony and purity10, 12 (Supplementary Fig. 1a, b).
To examine global alterations in the transcription of coding and
noncoding genes during EMT, we analyzed genome-wide tran-
scription proﬁles obtained via RNA-seq from NMuMG cells
treated with TGF-β at several consecutive time points repre-
senting untreated, early (day 1), intermediate (day 4), and late
(day 7) stages of EMT10. To identify previously unknown reg-
ulators of EMT that function in the nuclear compartment, we
performed a stepwise selection approach to obtain candidate
genes that are differentially expressed during EMT, contain a
nuclear localization signal, and are aberrantly expressed in var-
ious cancers (using the NextBio, cBioPortal, and Oncomine
databases). We further analyzed the expression patterns of these
candidates in other established model systems of EMT, including
TGF-β-induced EMT in a mouse Ras-transformed breast epi-
thelial cell line (EpRAS) and human primary mammary epithelial
cells (HMECs) (Fig. 1a, Supplementary Fig. 1c, f). We retained
only those candidates that showed consistent expression patterns.
These candidates were ﬁnally tested for their functional role using
loss-of-function experiments using a pool of four siRNAs tar-
geting the same gene, followed by extensive phenotypic and
molecular characterization. Among these candidates, FBXO32
emerged as the most potent regulator of EMT.
Fig. 1 FBXO32 is an essential regulator of phenotypic and transcriptional changes that are hallmark of EMT. a Schematic representation of in vitro EMT
induction and the identiﬁcation of previously unknown regulators. b Using RT-PCR, the levels of Fbxo32 mRNA in NMuMG cells during TGF-β-induced
EMT were measured relative to Ctcf and plotted on the y-axis. c FBXO32 mRNA level was measured by RT-PCR in primary human breast epithelial cells
(HMEC) undergoing TGF-β-induced EMT as described in Fig 1b. d, e Western blot analysis of FBXO32 in mouse NMuMG cell (d) and human HMECs (e)
undergoing TGF-β-induced EMT. Lamin and β-Actin acted as a loading control. f Representative bright-ﬁeld and immunoﬂuorescence images showing the
localization and expression levels of EMT marker proteins after 4 days (d4) of siRNA-mediated depletion of FBXO32 compared to non-targeting control
(siControl) in NMuMG cells. Staining was performed to assess the expression with antibodies against the epithelial markers E-cadherin and ZO1, the
mesenchymal marker N-cadherin, Fibronectin-1, Phalloidin (to visualize the actin cytoskeleton) and Paxillin (to detect focal adhesion plaques). Scale bar,
100 μm. g, h Using RT-PCR, the levels of FBXO32 and key EMT markers in NMuMG g and HMEC h cells transfected with either control siRNA or
independent siRNAs against FBXO32 during TGF-β-induced EMT were measured relative to CTCF and plotted on the y-axis. All experiments were
performed in biological triplicates unless otherwise speciﬁed. Error bars represent the SEM of three independent biological replicates (n= 3). *p< 0.05,
**p< 0.01, ***p< 0.001, Student’s t test. See also Supplementary Figs. 1–3
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Fbxo32 showed strong transcriptional induction during
TGF-β-induced EMT in NMuMG cells (Fig 1b, d, Supplementary
Fig. 2a). FBXO25, the closest evolutionarily conserved
member to FBXO32 (based on sequence and protein domain
similarity), remained transcriptionally unchanged during
EMT (Supplementary Fig. 2b, c). Furthermore, FBXO32
induction was dependent on TGF-β SMAD axis during
onset of EMT (Supplementary Fig. 2d), in line with previous
observations29, 32. Moreover, among all of the F-box-containing
proteins (n= 69), only Fbxo32 showed signiﬁcantly strong
upregulation during EMT (Supplementary Fig. 2e). In
line with these observations, a similar transcriptional induction
of Fbxo32 was observed in other EMT models in mouse
(EpRas cells) as well as human (primary human mammary
epithelial cells (HMEC) and MCF7 cells) (Fig. 1c, e,
Supplementary Fig. 2f, g).
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Next, we investigated the function of Fbxo32 during TGF-β-
induced EMT in mouse (NMuMG) cells using loss-of-function
approaches both by independent siRNAs and a pool of siRNAs to
ensure no off-target effects. Such depletion of Fbxo32 during
EMT led to a strong blockage in acquiring a mesenchymal state in
all tested cell types. This phenotype was conﬁrmed by an
immunoﬂuorescence assay that showed noticeable retention in
the epithelial markers (e.g., E-cadherin and ZO-1) at the
membrane, inability to acquire proper levels of crucial mesench-
ymal markers (e.g., N-cadherin, Fibronectin), and failure to
undergo cytoskeletal remodeling involving cortical actin, stress
ﬁbers, and focal adhesion formation (e.g., Phalloidin and Paxillin)
(Fig. 1f). Such blockage in undergoing EMT upon Fbxo32
depletion was further validated at RNA and protein levels for
several key EMT markers (Fig. 1g, Supplementary Fig. 2h). In
support of Fbxo32-dependancy of these changes, we could rescue
the phenotypic and molecular alterations upon Fbxo32 depletion
by overexpressing a siRNA-resistant FBXO32 (Supplementary
Fig. 2i, j). Importantly, all key ﬁndings were reproduced in
established human EMT model systems ((TGF-β-induced EMT
in HMEC and MCF7 cells)) (Fig. 1h, Supplementary Fig. 3a–d).
Together, these observations reveal FBXO32 is critical for
phenotypic and transcriptional changes underlying EMT.
FBXO32 induces genes that promote microenvironment
underlying EMT. Intrigued by the observed critical role of
FBXO32 in phenotypic and molecular changes during EMT, we
decided to investigate genome-wide transcriptional alterations
following FBXO32 depletion by a pool of four siRNAs during
EMT in HMEC. A computational analysis revealed that many
genes were signiﬁcantly differentially expressed, with more genes
downregulated (n= 231) than upregulated (n= 102), suggesting a
potential activating function of FBXO32 (Fig. 2a). This included
several established hallmark EMT genes such as CDH1, TJP3,
OCLN, CLDN1/3/11 (all epithelial makers), and CDH2, FN1,
VIM, ZEB1/2, SNAI1/2, TWIST1/2, (all mesenchymal makers)
that were upregulated and downregulated, respectively (Fig. 2b).
Interestingly, a deeper investigation of the downregulated genes
uncovered enrichment of important cytokines (interleukin and
CXCL family members), cytokine receptors (CXCR and
TGFBR1), extracellular matrix components (laminins and col-
lagens) and matrix metalloproteinases (MMPs, e.g., MMP1/3/9/
10), which are known to play critical roles in EMT (Fig. 2b). In
line with these ﬁndings, an analysis of the secretome in these cells
showed that the functional protein levels of these secretory
components, including several MMPs and cytokines, were
strongly downregulated upon FBXO32 depletion (Fig. 2c, d). The
downregulated genes from RNA-seq experiments showed
enrichment for ontologies related to cell migration, cell motility
and extracellular matrix organization, while the upregulated
genes showed enrichment for biological functions such as pro-
liferation, epithelium development and cell adhesion (Fig. 2e, f).
Interestingly, when we analyzed the expression dynamics of these
misregulated genes in epithelial cells, mesenchymal cells and cells
depleted of FBXO32, we found that FBXO32 depleted cells
retained a more epithelial-like gene expression proﬁle and were
unable to acquire a mesenchymal transcriptome (Fig. 2g). A
number of these genes were additionally validated for their
expression changes independently by RT-PCRs (Fig. 2h, i). These
ﬁndings suggest that FBXO32 plays a critical role in EMT by
regulating the underlying gene expression program, especially of
secretory cytokine and cellular matrix associated factors that are
essential to promote a suitable microenvironment for EMT
progression.
FBXO32 ubiquitinates CtBP1 to promote its nuclear retention.
Prompted by the critical role of FBXO32 in all the studied con-
texts of EMT, we sought to gain mechanistic insights into its
function. While FBXO32 depletion resulted in transcriptome
changes, given the known function of F-box-containing family
members as a component of the Ub ligase complex, and with
strong nuclear localization (Supplementary Fig. 4a, b), we hypo-
thesized that its gene regulatory function likely involves regulat-
ing the activity of other transcriptional regulators via post-
translational modiﬁcations. We therefore performed immuno-
precipitation of FBXO32, followed by liquid chromatography-
tandem mass spectrometry, to search for its possible interactors
and substrates (Fig. 3a). Among the most enriched candidates
detected by this analysis, we identiﬁed C-terminal-binding pro-
tein1 (CtBP1), which is known to play a key role in promoting
EMT15, 33, 34. This interaction between FBXO32 and CtBP1 was
further validated in independent co-immunoprecipitation assays
both following their overexpression and at the endogenous level
(Fig. 3b, c and Supplementary Fig. 4c, d). Intriguingly, this
interaction was abrogated by deletion of the large F-box domain
(115 aa, as predicted by InterPro, which encompasses the core F-
box domain of 45 aa) (Supplementary Fig. 4d). Since CtBP1 is
expressed at very similar levels during EMT and upon FBXO32
depletion (Supplementary Fig. 4e–g), we hypothesized that
FBXO32 regulates its function via post-translational
modiﬁcations.
FBXO32-mediated ubiquitination is known to cause both
activation of signaling cascades and proteasome-mediated
degradation26, 30. The overexpression of FBXO32 in human cells
resulted in an increased ubiquitination of CtBP1, which can be
blocked by Ub E1 inhibitor UBEI-41/ PYR-4135 (Fig. 3d,
Supplementary Fig. 4h). Moreover, FBXO32 overexpression led
to an increase in CtBP1 protein levels, whereas FBXO32 depletion
reduced the CtBP1 protein levels in both human and mouse EMT
model systems (Fig. 3e and Supplementary Fig. 4i–k). Due to a
poor transfection efﬁciency of primary HMEC cells, here we used
HMLE cells that originate from HMEC cells and show a similar
dynamics of EMT and FBXO32 induction (Supplementary
Fig. 4l)36, 37. We investigated whether the FBXO32-dependent
Fig. 2 FBXO32 induces genes critical for promoting a suitable microenvironment for EMT progression. a Volcano plots showing signiﬁcantly differentially
expressed genes upon FBXO32 depletion in HMECs undergoing EMT. b Heat map showing standardized expression (Z-scores) of key downregulated
genes along with EMT markers, upon FBXO32 depletion in HMEC cells undergoing EMT for 4 days. c, d Representative immunoblot (n= 3) of an individual
membrane array for human secretory MMPs (c) and cytokines (d) from HMEC cells upon FBXO32 depletion, and bar-graph showing their quantiﬁcations
on the right side. Control wells act as loading controls in our analysis to allow comparison of different blots. e, f GO analysis of downregulated (e) and
upregulated genes (f) upon FBXO32 knockdown in HMECs that underwent EMT for 4 days. g Heat map showing standardized expression (Z-scores) of
differentially expressed genes upon FBXO32 depletion in Epithelial HMEC cells, HMEC that underwent EMT for 4 days and treated with control siRNA-pool
or siRNA-pool against FBXO32. h, i The mRNA levels of downregulated genes (h) and upregulated genes (i) during EMT in control and FBXO32
knockdown HMECs that underwent EMT for 4 days were measured relative to CTCF via RT-PCR, and the results were plotted on the y-axis. Error bars
represent the SEM of three independent biological replicates (n= 3). *p< 0.05, **p< 0.01, ***p< 0.001, Student’s t test. See also Supplementary Figs. 2
and 3
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ubiquitination of CtBP1 has consequences on the subcellular
distribution of CtBP1. Strikingly, although CtBP1 is highly
localized to the nucleus under normal cellular conditions,
FBXO32 depletion resulted in CtBP1 localizing exclusively to
the cytoplasm in both human and mouse cells (Fig 3f and
Supplementary Fig. 5a). The degradation of proteins is known to
be mediated via K48-linked poly-Ub chains while K63-linked
ubiquitination is associated with the activation of signaling
pathways38. It is known that FBXO32 can perform both K48 and
K63-linked ubiquitination, which results in proteosome-mediated
degradation or nuclear localization of target proteins respec-
tively26, 30. Our further analyses showed that FBXO32 mediates
K63-linked ubiquitination, but not K48-linked ubiquitination of
CtBP1 (Fig 3g, Supplementary Fig. 5b). Moreover previous
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ﬁnding also indicates that additional non-K63 lysines are needed
for full ubiquitination as it partially rescued the ubiquitination
phenotype (Supplementary Fig. 5b). Together, these observations
establish that FBXO32 interacts with and modiﬁes CtBP1 to
promote its stability and nuclear retention.
Nuclear CtBP1 mediates epigenetic remodeling of EMT genes.
CtBP1 can repress or activate transcription by recruiting distinct
classes of epigenetic regulators39. To substantiate our ﬁndings
regarding a FBXO32-dependent role of CtBP1 in promoting
EMT, we depleted CtBP1 during EMT in human primary breast
epithelial cells. Such loss of CtBP1 led to an impaired EMT
similar to that observed following FBXO32 depletion (Supple-
mentary Fig. 6a). Encouraged by these ﬁndings, we performed
genome-wide gene expression proﬁling (RNA-seq) following
CtBP1 ablation in HMECs undergoing TGF-β-induced EMT.
Similar to FBXO32 knockdown, CtBP1 depletion led to a larger
number of downregulated genes compared to upregulated genes
(Fig. 4a). Importantly, a comparative analysis of the genes
downregulated upon CtBP1 depletion showed a highly signiﬁcant
overlap with the genes downregulated upon FBXO32 depletion
(Fig. 4b). The overlapping genes included MMPs and Cytokines,
which have established functions in signaling, cytoskeletal rear-
rangement and cell migration40–43 (Fig. 4b, Supplementary
Fig. 6b). Depletion of CtBP1 in FBXO32 overexpression back-
ground resulted in a reduced induction of its target genes (Sup-
plementary Fig. 6c). These ﬁndings validated FBXO32 as an
upstream regulator of CtBP1 during EMT.
Given our observations that FBXO32-mediated ubiquitination
of CtBP1 is required for its stability and nuclear retention, we
tested whether this is linked to CtBP1 chromatin binding and
epigenetic regulatory function at its target genes. In line with our
observations, we found that CtBP1 depletion impairs EMT
(Supplementary Fig. 6a) and reduces expression of genes which
were downregulated following FBXO32 knockdown (Fig. 4b, c).
Importantly, loss of FBXO32 led to a signiﬁcant reduction in
CtBP1 occupancy at promoters of key EMT relevant genes
(Fig. 4d). Since CtBP1 was previously reported to mediate gene
regulation via epigenetic mechanisms13, 16, we explored whether
CtBP1 depletion inﬂuences chromatin state of its target loci. In
line with the changes in gene expression, CtBP1 depletion led to a
substantial decrease in chromatin accessibility at the majority of
tested target promoters (Fig. 4e). Further analysis of active
histone modiﬁcations H3K4me3 and H3K27ac at these CtBP1
target promoters revealed a signiﬁcant decrease in their
enrichment upon FBXO32 depletion (Fig. 4f and Supplementary
Fig. 6d). Moreover, this also accompanied an increase in the
repressive mark H3K9me3 at these sites (Fig. 4g). Interestingly,
CtBP1 knockdown also lead to similar epigenetic changes at the
FBXO32 promoter, resulting in its transcriptional downregulation
(Fig. 4c–g). This indicates a possible feed-forward loop between
FBXO32 and CtBP1 that promotes EMT. All together, these
ﬁndings led us to conclude that FBXO32 mediates transcriptional
activation of key EMT genes, via CtBP1 targeting to their
promoters, and subsequent epigenetic remodeling that generates
a transcriptionally permissive state.
We investigated whether the genes regulated by FBXO32 and
CtBP1 are enriched for speciﬁc transcription factor binding
motifs. For this, we performed motif enrichment analysis at the
promoter regions of the genes that were deregulated following the
depletion of FBXO32 or CtBP1. This investigation at the
promoter of downregulated genes upon FBXO32 depletion
identiﬁed NFKB, activating transcription factor 3 (ATF3) and
BATF as the top motifs, whereas similar analysis for down-
regulated genes upon CtBP1 knockdown identiﬁed E2F6, BATF
and ATF3 as the top motifs (Fig. 4h, i). Since ATF3 was enriched
in both FBXO32 and CtBP1 targets, we attempted to further
validate these motif predictions using publically available
genome-wide binding (ChIP-seq) data sets for ATF3 in human
cells. Remarkably, majority of the FBXO32 and CtBP1 regulated
gene loci showed experimental evidence of ATF3 occupancy
(Fig. 4j and Supplementary Fig. 7a). Further analysis showed that
while ATF3 pre-occupied these target sites in epithelial cells, the
stability of its binding during EMT strongly relied on FBXO32
and CtBP1 (Fig. 4k, l). Moreover, ATF3 depletion during EMT
led to a downregulation of these genes (Supplementary Fig. 7b).
These ﬁndings imply that ATF3 may cooperate with CtBP1 in
gene regulation at distinct loci during EMT.
Altogether, these range of ﬁndings conclude that the FBXO32-
dependent nuclear localization of CtBP1 is essential for CtBP1
binding to its targets, and the epigenetic remodeling required for
the gene expression changes, underlying EMT.
Neuronal migration during brain development requires
Fbxo32. We next asked whether FBXO32 functions similarly
during developmental EMT. In the developing brain during
cortical development, radial glial cells in the ventricular zone
(VZ) undergo asymmetric division and daughter cells migrate
toward the cortical plate (CP), passing through the sub-
ventricular zone (SVZ) via an EMT-like mechanism44 (Fig. 5a).
Interestingly, analysis of laser micro-dissected samples from the
VZ, SVZ and CP of the E14.5 mouse cortex revealed expression
changes in several EMT genes that closely mimicked classical
EMT (Fig. 5b). Further analysis of these data sets revealed a
signiﬁcant transcriptional induction of Fbxo32 during neuronal
EMT (Fig. 5c). These results were independently validated using
Fig. 3 FBXO32-mediated K63-linked ubiquitination of CtBP1 is required for its stability and nuclear retention. a Analysis of FBXO32 interaction partners by
afﬁnity puriﬁcation-mass spectrometry. Volcano plot of three replicate showing selected signiﬁcantly enriched proteins in FBXO32 immunoprecipitated
samples. HMLE cells were transfected with Flag-tagged FBXO32 or an empty vector and were induced with TGF-β for 4 days. FBXO32 and interaction
partners were immunoprecipitated using Flag afﬁnity resin, followed by their identiﬁcation via LC-MS/MS. b Western blot of immunoprecipitated samples
to validate FBXO32 and CtBP1 interactions. HEK293T cells were co-transfected with Myc-CtBP1 and Flag-HA-FBXO32 and anti-CtBP1 IP was performed.
Immunoblot was performed to detect FBXO32 and CtBP1. c Western blot of immunoprecipitated samples to validate FBXO32 and CtBP1 endogenous
interactions in MDA-MB-231 cell. FBXO32 IP was performed and Immunoblot was performed to detect CtBP1 and FBXO32. d HEK293 were transfected
with various tagged construct as mentioned in the ﬁgure. Four hours before immunoprecipitation MG132 was added for all conditions. Western blot for
CtBP1 (α-Myc) immunoprecipitated samples was performed to detect ubiquitin (α-HA) and CTBP1. β-Actin, FBXO32 and Ubiquitin were detected in Input
samples as controls. e Western blot to access protein stability, showing CtBP1 and FBXO32 protein levels at various time points after cyclohexamide
treatment in HMEC cells transfected with control siRNA or siRNA against FBXO32. β-Actin acted as a loading control. f Immunoﬂuorescence image
showing CtBP1 localization in control and FBXO32-depleted HEK293T cells. Magniﬁed images of the nuclei are provided in the lower left corner of each
image. Scale bar, 100 μm. g A similar analysis as in d, but co-transfected with modiﬁed ubiquitin to demonstrate FBXO32-mediated K63-linked
ubiquitination of CtBP1. Here, K63-R represents ubiquitin with lysine at position 63 modiﬁed to arginine. Similarly, in K48-R, lysine at position 63 modiﬁed
to arginine. See also Supplementary Figs. 4–6
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FAC-sorted CD133+ (VZ population) and NCAM+ cells (neu-
ronal populations) (Fig. 5d). In addition, the transcriptional
dynamics of Fbxo32 was conﬁrmed by RNA in situ hybridization
datasets in the developing mouse cortex (Fig. 5e). Such Fbxo32
upregulation during neuronal EMT in vivo also accompanied the
induction of previously identiﬁed Fbxo32-dependent EMT-rele-
vant genes (Supplementary Fig. 8).
To test the role of FBXO32 during cortical development, we
performed in utero electroporation of mouse cortex45 at E12.5
with GFP reporter plasmids containing either control shRNA or
validated shRNA against Fbxo32 and the mice were euthanized at
E16.5 for further analysis (Fig. 5f). While cells electroporated with
control shRNA participated normally in neurogenesis and
populated throughout the cortex four days post-electroporation,
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Fbxo32-depleted cells resided almost exclusively below the
SATB2-positive layer, which marks neurons (Fig. 5g, h). These
observations were further conﬁrmed by a binning analysis of the
electroporated cortices (Fig. 5g, i). Such retention of Fbxo32-
depleted cells in the VZ/SVZ suggested a potential defect in
cellular migration that is known to involve EMT. Moreover,
FBXO32 was also found to be induced during human in vitro
neurogenesis (Fig. 5j)46. Overall, these observations indicate
FBXO32 as a critical player in neuronal EMT during brain
development.
Tumor aggressiveness correlates with FBXO32 expression
levels. Prompted by our observations of a critical function of
FBXO32 during EMT, we investigated its expression in a wide
range of human tumors. A large-scale analysis of several well-
characterized human clinical expression data sets revealed an
exceptionally strong ampliﬁcation of FBXO32 in a majority of
human tumors (Fig. 6a). Computational analyses revealed sig-
niﬁcantly higher expression of FBXO32 in various tumors com-
pared to the matched normal tissues (Fig. 6b, c and
Supplementary Fig. 9a–d). In support of our observations,
FBXO32 levels correlated positively with the levels of established
mesenchymal markers and negatively with the levels of epithelial
markers in different types of tumor examined (Supplementary
Fig. 9e–f). A survival analysis of the clinical breast tumor data sets
revealed a signiﬁcant correlation between higher FBXO32
expression and poor relapse-free and metastasis-free survival
(Fig. 6d, e). Moreover, FBXO32 expression showed the expected
correlation with the levels of established EMT markers as well as
the identiﬁed FBXO32-induced EMT genes in multiple cancers,
corroborating its critical role during human tumor metastasis
(Fig. 6f–i). A deeper analysis of various tumor data sets (breast,
colon, gastric, lung, and ovarian tumor) further validated these
ﬁndings (Supplementary Fig. 9g–l, and 10a–c). In addition,
transcriptome analysis of a large set of cancer cell lines conﬁrmed
an enhanced expression of FBXO32 in mesenchymal cancer cell
lines as compared to epithelial counterparts (Fig. 6j). To ulti-
mately validate these ﬁndings in clinical samples, we collected
non-invasive and invasive breast tumor samples (n= 20 each)
and analyzed the expression of FBXO32 in these samples. In line
with our previous observations, FBXO32 expression was sig-
niﬁcantly higher in the invasive tumors compared to the non-
invasive tumors (Fig. 6k). Overall, these comprehensive set of
observations extend our ﬁndings to the clinic and suggest a role
for FBXO32 in promoting tumorigenicity and metastasis in
humans.
FBXO32 promotes tumorigenicity and metastasis in mouse
model. To functionally assess the contribution of FBXO32 to the
mesenchymal state in a disease context, we investigated FBXO32
expression in certain tumor cell lines that are routinely used for
such studies. In line with our earlier observations (Fig. 6j),
FBXO32 expression was signiﬁcantly higher in human
mesenchymal cancer cell lines (MDA-MB-231 and BT547)
compared to human epithelial cancer cell lines (MCF7 and MDA-
MB-361) (Fig. 7a, b). Next, we depleted FBXO32 in these cell lines
and assessed their proliferation and colony-forming capacity.
While the epithelial cell lines did not exhibit any obvious effects,
the mesenchymal cells showed signiﬁcantly reduced proliferation
(Supplementary Fig. 11a). Moreover, depletion of FBXO32 in the
mesenchymal breast cancer cell line (MDA-MD-231) led to a
signiﬁcant reduction in their migration and invasion potential
(Fig. 7c, d). Encouraged by these observations, we performed
global gene expression proﬁling (RNA-seq) in FBXO32-depleted
MDA-MB-231 cells. Similar to our previous ﬁndings during EMT
in HMEC, FBXO32 depletion led to a signiﬁcant downregulation
of 704 genes and an upregulation of only 280 genes (Fig. 7e). The
downregulated genes included many migration-relevant genes,
such as cytokines (e.g., IL6/8/18, CXCL2/3) (Supplementary
Fig. 11b).
MDA-MB-231 cells have been reported to form tumors and
metastasize to distant organs in mouse models47. To further
investigate the role of FBXO32 in primary tumor growth and
metastasis formation, we generated MDA-MB-231 cells (contain-
ing GFP and a luciferase reporter) with stable integration of a
control shRNA or validated shRNA against FBXO32. Our
analysis showed no defects in proliferation or signs of apoptosis
in these cells stably depleted of FBXO32 (Supplementary
Fig. 11c–e). Similarly, in vitro sphere formation assay did not
reveal any obvious alterations in cell proliferation and colony
forming ability (Supplementary Fig. 11f, g). These cells (pool of
cells with stable integration) were xenografted into the mammary
fat pad of NOD SCID gamma (NSG) mice (n= 6), and tumor
growth and metastasis to distant organs were quantiﬁed at regular
intervals. The primary tumor growth was severely reduced in the
absence of FBXO32 over time (Fig. 7f, g). Importantly, the
FBXO32-depleted tumor cells were unable to migrate to distant
organs, as measured by in vivo luciferase activity at day 50
(Fig. 7h–k). These data were veriﬁed by analyzing the parental
tumor cells using GFP staining in the lungs, which is known to be
the preferred destination of these tumor cells following metastasis
(Fig. 7l). Gene expression analysis of primary tumors depleted of
FBXO32 also validated downregulation of previously identiﬁed
FBXO32-dependent genes (Fig. 7m). Hematoxylin and eosin
Fig. 4 FBXO32-dependent nuclear localization of CtBP1 is essential for epigenetic and transcriptional remodeling of critical EMT genes. a Differential
expression analysis showing signiﬁcantly differentially expressed genes upon CtBP1 depletion in HMECs undergoing EMT for 4 days. b A venn diagram
showing the overlap of downregulated genes upon CtBP1 and FBXO32 depletion in HMECs undergoing EMT for 4 days and on the right hand, heat map
showing their expression along with epithelial HMEC. c RNA-seq data showing the mRNA levels of key EMT-associated deregulated genes upon CtBP1
depletion. The y-axis represents the normalized tag count. d ChIP assay using an anti-Myc antibody to assess the binding of Myc-CtBP1 to its target
promoter in HMLE cells induced with TGF-β for 4 days and transfected with either control siRNA or siRNA against FBXO32. q-PCR was performed for the
indicated gene promoters, and gene enrichment was plotted on the y-axis as the ratio of precipitated DNA (bound) to total input DNA and normalized with
intergenic region. e FAIRE assay was performed to assess the chromatin accessibility of EMT-associated deregulated genes in HMLE cells induced with
TGF-β for 4 days and transfected with control siRNA or siRNA against CtBP1. Quantitative PCR was performed for the indicated gene promoters, and gene
enrichment was plotted on the y-axis as the ratio of precipitated DNA (bound) to total input DNA and normalized with intergenic region. f, g A similar
analysis as in d but ChIP performed for the H3K4me3 mark (f) and H3K9me3 mark (g). h, i Enriched motifs at the promoters of downregulated genes upon
FBXO32 and CtBP1 knockdown (h) and (i) respectively. j A Venn diagram showing the presence of ATF3 motifs on or in close proximity to the promoters
of genes that were downregulated upon FBXO32 and CtBP1 knockdown in HMEC. k A similar analysis as in d but with ChIP performed in HMLE cell for
ATF3 and gene enrichment was plotted on the y-axis as % of total input. IgG were run as a control. l ATF3 ChIP were performed in HMLE cells undergoing
TGF-β induced EMT and depleted for FBXO32 or CtBP1 and gene enrichment was plotted on the y-axis as % of total input and normalized to intergenic
region. For all above experiments the error bars represent the SEM of three independent biological replicates (n= 3). *p< 0.05, **p< 0.01, ***p< 0.001,
Student’s t test. See also Supplementary Fig. 7
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(H&E) staining on these tumors showed a more compact
organization of cells in FBXO32 depleted primary tumors as
compared to the control tumors, which may be linked to the
reduced metastatic behavior of FBXO32-depleted tumor cells
(Fig. 7n). We also observed a clear decrease in the levels of
secretory cytokines such as IL8, NGFR and GM-CSF in FBXO32-
depleted tumors which may be associated with their compro-
mised migratory potetial (Fig. 7o). Furhermore, MDA-MB-231
cells in culture as well as primary tumors from mouse xenograft
experiments showed strongly reduced CtBP1 levels in the nuclear
compartment following FBXO32 depletion (Supplementary
Fig. 11h, i). Altogether these in vivo observations establish a
critical role for FBXO32 in promoting tumorigenicity and
metastasis.
Discussion
The differentiation of epithelial cells into motile mesenchymal
cells, a process known as EMT, is integral in development and
wound healing and it contributes pathologically to ﬁbrosis and
cancer progression. EMT involves action of transcription factors
such as SNAIL, ZEB, and TWIST, the functions of which are
ﬁnely regulated at the transcriptional, translational and post-
translational levels. These key transcription factors utilize various
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cofactors, such as CtBPs, to recruit chromatin-modifying com-
plexes to modulate the expression of genes13, 16, 33, 34. In tissues,
EMT is regulated via signaling by soluble growth factors (e.g.,
TGF-β and cytokines), composition and structure of extracellular
matrix (ECM), and ECM remodeling enzymes (e.g., MMPs)40, 48.
Recent discoveries have shed light on the importance of post-
translational modiﬁcations, such as ubiquitination, during
EMT49, 50. The K48 linked poly-ubiquitination of target proteins
leads to proteasome-mediated degradation51, whereas K63-linked
ubiquitination has been implicated in the activation of several
signaling pathways52. However, little is known about how the Ub
pathway contributes to the epigenetic reprogramming that drives
the gene expression program underlying EMT.
A genome-wide transcriptome analysis, in a previously char-
acterized and established cellular model system of EMT using
PMEC, identiﬁed strong transcriptional induction of F-box pro-
tein, FBXO3210, 12. FBXO32 generally acts as a substrate-
recognition subunit of the SKP1–Cullin1–F-box protein E3
ligase complex for ubiquitination and was shown to have a role in
muscle homeostasis25, 53. We found that FBXO32 is directly
modulated by TGF-β SMAD axis of EMT progression (Supple-
mentary Fig. 2d)32 and robustly induced during various contexts
of EMT, irrespective of species and cell type. We found that
FBXO32 depletion results in a phenotypic blockage of EMT in
various established human and mouse cellular models, which was
accompanied by a failure to gain expression of core EMT driver
TFs, such as SNAIL, ZEB and TWIST, suggesting a critical
requirement for FBXO32 in mediating the EMT process.
Extending these ﬁndings to cancer metastasis as an example of
disease EMT, we found that FBXO32 was strongly ampliﬁed in
metastatic cancers, and its depletion in a NSG mouse xenograft
model signiﬁcantly inhibited tumor growth and metastasis.
During gastrulation, pluripotent epithelial epiblast cells ingress to
form the primary mesoderm through EMT8. Similar phenomena
have been observed during later embryogenesis and organ
development, such as cortical neurogenesis, where the neural
stem cells from the ventricular zone undergo changes in polarity
and ultimately migrate towards the cortex54. Our ﬁndings of an
impaired neuronal EMT during brain development following
FBXO32 depletion in vivo imply that FBXO32 is a critical player
and member of the core EMT machinery that mediates EMT in
both developmental and disease contexts. These observations are
also in line with the concept that the transition of epithelial cells
into mesenchymal cells, both in development and under patho-
logical conditions, follows a conserved program55.
FBXO32 contains a class II PDZ domain that interacts with
speciﬁc sequences at the C-terminal of its target proteins, and it
has two nuclear localization signals56. PZD domain helps in
localizing cellular elements, and regulating cellular pathways.
These aspects of FBXO32 suggest that it may target transcription
factors or other proteins in the nucleus for ubiquitination. Our
global proteomics approach identiﬁed many FBXO32 interactors
and substrates, among which CtBP1 was very strongly enriched.
CtBP1 lacks nuclear localization signal and it is assumed that its
hetero-dimerization with other proteins (e.g., CTBP2, KLF3)
allows its translocation to the nucleus14. While a previous study
indicated that the Pak1-mediated phosphorylation of CtBP1
causes its cytoplasmic retention57, nothing is known about what
results in its nuclear retention. Our comprehensive investigation
revealed that FBXO32-dependent K63-mediated ubiquitination of
CtBP1 is essential for its nuclear retention. We also ﬁnd that a
deletion within FBXO32 encompassing the core F-box domain
results in a loss of its interaction with CtBP1. It is possible that
the amino acids that were deleted in addition to the core F-box
play an essential role in the interaction of FBXO32 with its
substrate CtBP1. Such deletion may also affect binding of other
factors directly or indirectly, which in turn could cause a loss of
FBXO32 interaction with CtBP1. Future work should involve a
more ﬁne mapping of amino acid residues that are involved in
FBXO32 function, including its substrate recognition. It is known
that CtBP1 functions in cooperation with other chromatin
remodelers such as KDM1A and transcription factors including
SNAIL, ZEB13. Our experimental evidences revealed that
FBXO32-dependent nuclear localization of CtBP1 is essential for
its binding at the promoters of key EMT genes and subsequent
epigenetic remodeling, including histone modiﬁcations and
chromatin accessibility, thereby generating the gene expression
program that drives EMT.
Among the most interesting observations following depletion
of FBXO32 during EMT was the ﬁnding that the expression
pattern of not only the established hallmark EMT genes but also a
majority of EMT relevant genes was closely retained in an
epithelial-like state. Interestingly, these data also revealed that
MMPs (e.g., MMP1, MMP9, and MMP10), which degrade and
modify the ECM and play a crucial role in EMT, require FBXO32
for their transcriptional induction during EMT. MMP1 cleaves
and activates protease-activated receptor-1 (PAR-1), leading to
increased migration and invasion of breast cancer cells40. Simi-
larly, MMP9 mediated proteolytic activation of latent TGF-β and
interleukin-8, results in a positive feed-forward loop for EMT
progression40. An inﬂammatory tumor microenvironment is
known to play a pivotal role in the development of cancer58.
Notably, inﬂammatory cytokines such as CXCL1/2/3/5, IL-1A/1B/
32/6, and many of their receptors, such as IL1R1, CXCR1 and
Fig. 5 FBXO32 is required for neuronal EMT during brain development. a Schematic representation of cellular morphology changes in a developing mouse
cortex (E14.5) across its various layers viz. ventricular zone (VZ), sub‐ventricular zone (SVZ), intermediate zone (IZ) and cortical plate (CP). b Normalized
tag counts for key EMT markers in RNA-seq data derived from the ventricular zone (VZ), the sub-ventricular zone (SVZ), and the cortical plate (CP) of
E14.5 mouse cortex. c The levels of Fbxo32 mRNA are shown as the average normalized tag counts derived from the RNA-seq data used in (b). d RT-PCR
analysis of Fbxo32 in FAC-sorted cells from E14.5 mouse cortex using antibodies against CD133 and NCAM surface markers. The mRNA levels were
measured relative to Ctcf via RT-PCR, and the results were plotted on the y-axis. Error bars represent the SEM of independent biological replicates (n= 3).
e The expression pattern of Fbxo32 mRNA as visualized by in situ hybridization in E14.5 cortex. The data were extracted from the publically available data
set “gene paint.” f Graphical representation of in utero electroporation (IUE). g In utero electroporation was performed at E12.5 using plasmids containing
GFP and with control shRNA or shRNA against Fbxo32, and the mice were euthanized at E16.5 for further analyses. A representative image (n= 3) of the
immunoﬂuorescence analysis performed with anti-GFP and anti-SATB2 antibodies showing the retention of GFP-positive cells below the SATB2 layer in a
brain electroporated with Fbxo32 shRNA compared to a control brain. h A bar plot showing quantiﬁcation of the migrated GFP-positive cells in control and
Fbxo32-depleted mouse brains with respect to SATB2 staining. The y-axis represents the percentage of cells on or below the Satb2-stained region. The
error bars represent the SEM of three independent biological replicates. *p< 0.05, Student’s t test. i The cortex was divided into ﬁve equal bins as shown in
g, and the number of electroporated cells was counted in each bin. The percentage of cells in each bin was plotted on the y-axis. Error bars reﬂect the S.E.
M. of quantiﬁcations from independent brains, and signiﬁcance was calculated using a t-test comparing shControl and shFbxo32 electroporated brains
(*< 0.05) (n= 3). j The expression of FBXO32 during human neurogenesis in vitro is depicted using normalized tag counts from RNA-seq data for various
stages of this process in a previous study46. See also Supplementary Fig. 8
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TGFBR1, were also strongly induced by FBXO32. Altogether,
these evidences emphasize the essential function of FBXO32 in
establishing the microenvironment required to initiate EMT.
Further computational and experimental analysis also dis-
covered that the genes activated by FBXO32 via CtBP1 are also
targeted by ATF3. ATF3 is induced by a variety of signals,
including TGF-β, and is known to play an integral role in
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upregulating TGF-β target genes, including SNAIL, SLUG, and
TWIST, to enhance cell motility59. These data suggest that other
branches of signaling induced by TGF-β during EMT may con-
verge and/or cooperate with FBXO32–CtBP1 axis to modulate
expression of key EMT genes. It will be interesting to further
dissect this network and unravel its relevance in ﬁne-tuning the
gene expression program underlying EMT.
We further discovered that FBXO32 not only promotes EMT
but also plays a critical role in the maintenance of mesenchymal
identity by regulating a distinct set of genes in each case. Since
EMT plays a critical role in tumorigenicity and metastasis, we
interrogated a large panel of human cancers for FBXO32
expression and revealed a very strong induction of FBXO32 in
various tumor types compared to the matched normal tissues.
Moreover, an elevated FBXO32 expression signiﬁcantly correlated
with poor relapse-free, overall, and metastasis-free survival in
patients with tumors of various origins, including breast, colon,
lung, gastric and ovary. Moreover, FBXO32 levels correlated
positively with the levels of established mesenchymal markers and
identiﬁed FBXO32-induced EMT genes, while it negatively cor-
related with the levels of epithelial markers in all studied tumor
types. Of note, within tumors, FBXO32 was more highly
expressed in invasive tumors compared to non-invasive tumors.
These ﬁndings are in full agreement with our observations of
signiﬁcantly reduced metastatic potential of breast cancer cells
in vitro and in vivo following FBXO32 depletion. These range of
ﬁndings and validations, in several model systems and primary
cells from human and mouse, establish a critical role of FBXO32
in promoting tumorigenicity and metastasis in cancers.
TGF-β signaling pathways exert tumor suppressor effects in
normal cells and early carcinomas. As tumors develop and pro-
gress, these protective and cytostatic effects of TGF-β are often
lost due to cellular dynamics which can selectively shut down the
tumor suppressive axis and TGF-β signaling then switches to
promote cancer progression, invasion, and tumor metastasis60, 61.
This could also explain why few previous studies found FBXO32
to function as a tumor suppressor in gastric and urothelial car-
cinoma downstream of TGF-β signaling31, 32, while our own
observations made in multiple model systems including primary
EMT, metastatic cancer cell lines and clinical samples conclude
that FBXO32 functions as a promoter of tumorigenicity and
metastasis. Interestingly, various components of TGF-β signaling
pathways are known to be primarily mutated in distinct tumor
types such as colon, ovarian, and uterian carcinomas, but strongly
ampliﬁed in breast, lung, pancreas, esophagus, and stomach
carcinomas61. Our analysis showed a massive ampliﬁcation of
FBXO32 in several tumor types which was very strong for most
breast tumor datasets.
Altogether, our ﬁndings provide the ﬁrst report on FBXO32 as
a highly potent and new regulator of EMT in both development
(e.g., neurogenesis) and disease (e.g., cancer metastasis) contexts
of EMT. We show that FBXO32 plays a critical role in the pro-
gression and maintenance of mesenchymal identity by regulating
the expression of key mesenchymal genes, including MMPs,
chemokines, chemokine receptors and the extracellular matrix
components. The FBXO32-mediated ubiquitination of CtBP1
promotes its nuclear localization, which is essential for its chro-
matin remodeling function at the target key EMT genes to
mediate the gene expression program that drives EMT (Fig. 8).
Together, these ﬁndings establish the function of FBXO32 as a
critical regulator of EMT by governing the gene expression pro-
gram underlying this process during development and disease.
Methods
Reagents. The reagents used in the present study were TGF-β (rhTGF-β1 240-B,
R&D Systems), DMEM (21969-035, Invitrogen), RPMI-1640 (R0883, Sigma), PBS
(D8537, Sigma), trypsin (25300-054, Invitrogen), Opti-MEM (31985-047, Invitrogen),
FBS (10270, Invitrogen), glutamine (25030-024, Invitrogen), MEM NEAA (100×)
(11140-035, Invitrogen), Lipofectamine 2000 (11668, Invitrogen), Lipofectamine
RNAiMAX (13778-150, Invitrogen), Trizol (15596026, Invitrogen), reverse tran-
scriptase kits (K1612, Thermo Fischer), SYBR-Green PCR MasterMix (4334973,
Invitrogen), Bradford reagent (5000205, BioRad), a protease inhibitor cocktail
(04693132001, Roche), and a phosphatase inhibitor cocktail (04906837001, Roche).
Inhibitors used in the study. For chemical inhibition experiments, we used JNK
inhibitors, SP600125, (10 μM) (S5567, Sigma), ERK-signaling inhibitors UO126
(25 μM) (Milipore) and p38i SCIO-469, (5 nM), (3528, r&d systems). Ubiquiti-
nation pathway inhibitor PYR-41 or 4[4-(5-Nitro-furan-2-ylmethylene)-3,5-dioxo-
pyrazolidin-1-yl]-benzoic acid ethyl ester (N2915, Sigma) was added to cell culture
medium to a ﬁnal concentration of 10 µM, 4 h prior to collection of cells.
The cells were seeded at required densities and pretreated 30 min prior to TGF‐
β treatment with signaling pathway inhibitors or their solvent control DMSO at the
ﬁnal concentrations, mentioned above and analyzed at indicated time points. For
SMAD pathway blocking, we have used on target plus smart pool siRNA
(Dharmacon) targeting Smad4. This was followed by collecting the cells 24 h later
for RNA analysis.
Antibodies used for western blot, immunoprecipitation and immuno-
ﬂuorescence assays. The antibodies used for immunoﬂuorescence were against E-
cadherin (13-1900, Invitrogen and 610182, BD Transduction Laboratories), N-
cadherin (610921, BD Transduction Laboratories), ZO-1 (617300, Invitrogen),
ﬁbronectin (F-3648, Sigma-Aldrich), paxillin (610052, BD Transduction Labora-
tories), GFP (chicken, Aves Labs), SATB2 (Abcam, ab34735), beta-actin (C4, sc-
47778, Santa Cruz), FBXO32 (sc-33782, Santa Cruz) (ab168372), ZEB1 (sc-25388 (H-
102) Santa Cruz), ATF-3 (sc-188 (C-19) Santa Cruz), Cleaved caspase 3 (Asp175,
9661 S, cell signaling), FLAG tag M2 (F1804, Sigma), HA tag monoclonal antibody
(c15200190, Diagenode), Myc tag (ab9106, Abcam), Ub mouse monoclonal (sc8017,
Santa Cruz), Lamin B (sc-6216 (C-20), Santa Cruz), Histone H3 tri methyl K4,
(ab12209, Abcam), Histone H3 tri methyl K9, (ab8898, Abcam), Histone H3 acetyl
K27, (ab4729, Abcam), Alexa Fluor-488 goat anti-mouse IgG (H + L) (A11029,
Invitrogen); Alexa Fluor-568 goat anti-rabbit IgG (H + L) (A11011, Invitrogen), Alexa
Fig. 6 FBXO32 expression correlates with tumor aggressiveness. a Bar plot showing the frequencies of mutations, deletions, ampliﬁcations and multiple
alterations in well-characterized transcriptomes and genomic datasets of different tumors of various origins available from CBioPortal. The x-axis shows
various types of tumors, and the y-axis represents the percentage of tumors with a speciﬁc defect. b, c Box plots showing expression level of FBXO32 in
normal vs tumor samples in two well-characterized clinical tumor datasets for breast (b) and pancreas (c) origin. Box plots represent the 25th to 75th
quartiles with the bold horizontal line representing the median value. d, e A Kaplan-Meier analysis was performed for the Breast tumor datasets. Survival
curves showing decreased relapse free survival (d) and decreased metastasis free survival (e), which was signiﬁcantly correlated with higher FBXO32
expression. f, g Box plots showing levels of key EMT markers expression in the clinical breast tumor databases used in Fig. 5d, e, respectively, and split
based on expression of FBXO32. For all such analyses, here and later, we considered the ﬁrst and forth quartile of patient samples ordered based on the
median expression of FBXO32. The best probe was considered for analysis, if provided by the manufacturers. Box plots represent the 25th to 75th quartiles
with the bold horizontal line representing the median value. h, i Gene set enrichment analysis showing correlation between genes downregulated upon
FBXO32 depletion and the genes associated to the speciﬁed GO terms, as a function of fold change between expression levels of these genes in tumors
with high FBXO32 and low FBXO32 expression in the characterized tumor data sets in Fig. 5d, e, respectively. P value for fold change, Enrichment score
(ES), Normalized Enrichment Score (NES) and FDR q-value were provided in the ﬁgure j The levels of FBXO32 mRNA in epithelial (n= 256) and
mesenchymal (n= 249) cancer cell lines are shown as the FPKM derived from the publically available RNA-seq data (C Klijn et al, 2015) and the results
were plotted on the y-axis. k The levels of FBXO32 mRNA in non-invasive (DCIS) (n= 20) and invasive tumor samples (n= 20) were measured relative to
TBP via RT-PCR, and the results were plotted on the y-axis. *p< 0.05, Student’s t test. See also Supplementary Figs. 9 and 10
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Fluor-633 goat anti-rat IgG (H + L) (A21094, Invitrogen), and Alexa Fluor-633
phalloidin (A22284, Invitrogen), which was used to stain F-actin.
Cell culture. HMECs were obtained from Lonza and cultured according to the
manufacturer’s guidelines. Other cell lines were obtained from ATCC and cultured in
the following media: MDA-MB-231: DMEM, 10% FBS; MDA-MB-361: DMEM, 20%
FBS; BT549: RPMI-1640, 10% FBS, 0.001mg/ml bovine insulin; MCF7: DMEM, 10%
FBS, 0.01mg/ml bovine insulin; HEK293T: the same medium as NMuMG. HMLE
cells were a kind gift from Christina Scheel (Helmholtz Zentrum Munich) and cul-
tured in LONZA primary cell culture medium. A subclone of NMuMG cells was
grown in DMEM supplemented with 10% FBS, 2mM L-glutamine and 1× non-
essential amino acids62. All the cells were cultured at 37 °C with 7% CO2 in a humid
incubator. For TGF-β time-course experiments, NMuMG, HMEC and HMLE cells
were treated with 2, 5 and 5 ng/ml TGF-β, respectively, for the indicated times. TGF-β
was replenished and the medium was changed every 2 days.
siRNA-mediated knockdown. For all siRNA-mediated knockdown experiments,
the cells were seeded at the same starting density and transfected every second day
with ON-TARGET plus single siRNA or SMART pool siRNAs (i.e., a mixture of
4 siRNAs provided as a single reagent) (Dharmacon). For siRNA transfections,
Lipofectamine RNAiMAX (Invitrogen, 13778-150) was used according to the
manufacturer’s instructions. For experiments during TGF-β-induced EMT, TGF-β
induction was performed at the same time that siRNA was added to avoid indirect
effects due to loss of protein function. The sequences of the siRNAs are provided in
Supplementary Data 1.
Mammosphere culture. For primary sphere formation, single cells were plated in
ultralow attachment plates (Corning) at a density of 20,000 viable cells/mL in
serum-free mammary epithelial growth medium composed of DMEM supple-
mented with 1% L-glutamine, 1% penicillin/streptomycin, 30% F12, 2% B27
(Invitrogen), 20 ng/mL EGF (peprotech, AF-100-15) and 20 ng/mL bFGF
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(peprotech, 100-18B). The medium was made semi-solid by the addition of 0.5%
Methylcellulose (Sigma) to prevent cell aggregation. Mammospheres were collected
by gentle centrifugation (200 g) after 10 days and dissociated enzymatically (10 min
in 0.05% trypsin, 0.53 mM EDTA, Invitrogen) and mechanically, using a ﬁre-
polished Pasteur pipette. The cells obtained from dissociation were sieved through
a 40-μm sieve and analyzed microscopically for single-cellularity. For the secondary
sphere formation, 1000 cells/ml were plated and colonies were monitored by a
microscope at a regular interval.
Immunoﬂuorescence assay. The cells were grown on coverslips, ﬁxed with 4%
paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100 for 15 min at
room temperature. Subsequently, the cells were blocked with 10% goat serum, 5%
FCS and 0.5% BSA in PBS for 20 min and were incubated with primary antibodies
at 4 °C overnight. The cells were then incubated with ﬂuorochrome-labeled sec-
ondary antibody or Phalloidin-633 for 1 h at room temperature. The coverslips
were counterstained with Hoechst, mounted with immu-mount and imaged using
a confocal laser-scanning microscope. The data were processed by ImageJ software.
Immunohistochemistry for analysis of mouse cortex. The isolated E16.5
embryonic brains were immediately ﬁxed for 6 h in 4% PFA in PBS at 4 °C. The
brains were then cryoprotected in 10% sucrose for 2 h and then in 30% sucrose (in
PBS) overnight, embedded in Tissue-Tek, stored at −20 °C and cryo-sectioned at
12 μm. Sections on coverslips were preblocked with 2% BSA and 0.5% Triton (in
PBS) for 1 h. Primary antibodies (Satb2, 1:500, and anti-GFP (chicken, Aves Labs,
1:1000)) were applied in blocking solution overnight at 4 °C. Fluorescent secondary
antibodies were applied according to the manufacturer’s protocol (Life Technol-
ogies). The coverslips were counterstained with Hoechst, mounted with immo-
mount and imaged using a confocal laser-scanning microscope (Leica SP5). The
data were processed with ImageJ software.
Quantitative real time PCR. mRNA levels were quantiﬁed as previously descri-
bed12. In brief, total RNA was prepared using Trizol (Invitrogen) or a SurePrep
TrueTotal RNA Puriﬁcation Kit (Fisher Scientiﬁc) and was reverse transcribed with
a First Strand cDNA Synthesis Kit (Fermentas). The transcripts were quantiﬁed via
PCR using SYBR green PCR MasterMix (ABI) on a ViiA7 PCR machine (Life
Technologies). Human or mouse CTCF/Ctcf and TBP/Tbp primers were used for
normalization. The sequences of all of the primers used in this study are listed in
Supplementary Data 1.
Immunoblotting. The cells were lysed in RIPA buffer, and protein concentrations
were quantiﬁed using Bradford reagent. Equal amounts of protein (30 µg) were
boiled in 6 × SDS-PAGE loading buffer, subjected to polyacrylamide gel electro-
phoresis, transferred to a PVDF membrane and probed with the appropriate
antibodies. All uncropped western blot images can be found in Supplementary
Fig. 12.
Chromatin Immunoprecipitation assay. The cells were cross-linked in medium
containing 1% formaldehyde for 10 min at room temperature, neutralized with
0.125 M glycine, scraped, and rinsed twice with PBS. The pellets were suspended in
buffer L1 (50 mM Hepes KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8.0, 10%
glycerol, 5% NP-40, and 0.25% Triton-X 100) and incubated for 10 min at 4 °C.
The cells were then suspended in buffer L2 (200 mM NaCl, 1 mM EDTA pH 8.0,
0.5 mM EGTA pH 8.0, 10 mM Tris pH 8.0) for 10 min at room temperature.
Finally, the pellet was suspended in buffer L3 (1 mM EDTA pH 8.0, 0.5 mM EGTA
pH 8.0, 10 mM Tris pH 8.0, 100 mM NaCl, 0.1% Na-deoxycholate, 0.17 mM N-
lauroyl sarcosine) containing protease inhibitors and was incubated at 4 °C for 3 h
following sonication using Bioruptor plus (Diagenode). Sixty micrograms of
chromatin was incubated overnight at 4 °C with 2 μg of the antibodies targeting
H3K4me3, H3K9me3, H3K27ac (Abcam) or Myc (Santa Cruz) and then incubated
with preblocked beads for 4 h. Finally, the beads were washed twice with L3 and
once with 1 ml of DOC buffer (10 mM Tris (pH 8.0), 0.25 M LiCl, 0.5% NP-40,
0.5% deoxycholate, 1 mM EDTA), and the bound chromatin was eluted in 1% SDS/
0.1 M NaHCO3. This followed treatment with RNase A (0.2 mg/ml) for 30 min at
37 °C and then with proteinase K (50 µg/ml) for 2.5 h at 55 °C. The crosslinking
was reversed at 65 °C overnight with gentle shaking. The DNA was puriﬁed by
phenol-chloroform extraction followed by ethanol precipitation and was recovered
in TE buffer.
Mass spectrometry analysis. Peptide fractions were analyzed using a quadrupole
Orbitrap mass spectrometer (Q Exactive Plus, Thermo Scientiﬁc) equipped with a
UHPLC system (EASY-nLC 1000, Thermo Scientiﬁc), as described63. Peptide
samples were loaded onto C18 reversed-phase columns and eluted for 2 h with a
linear gradient of acetonitrile from 8 to 40% containing 0.1% formic acid. The mass
spectrometer was operated in data-dependent mode with automatic switching
between MS and MS2 acquisition. Survey full scan MS spectra (m/z 300–1650)
were acquired in the Orbitrap. The 10 most intense ions were sequentially isolated
and fragmented by higher-energy C-trap dissociation (HCD)64. Peptides with
unassigned charge states or charge states less than +2 were excluded from frag-
mentation. The fragment spectra were acquired in the Orbitrap mass analyzer.
Peptide identiﬁcation: the raw data ﬁles were analyzed using MaxQuant
(development version 1.5.2.8)65. Parent ion and MS2 spectra were searched against
a database containing 88,473 human protein sequences obtained from the
UniProtKB released in December 2013 using the Andromeda search engine66. The
spectra were searched with a mass tolerance of 6 ppm in MS mode, 20 ppm in
HCD MS2 mode, strict trypsin speciﬁcity and allowing up to 3 miscleavages.
Cysteine carbamidomethylation was searched as a ﬁxed modiﬁcation, whereas
protein N-terminal acetylation and methionine oxidation were searched as variable
modiﬁcations. The data set was ﬁltered based on posterior error probability (PEP)
to arrive at a false discovery rate below 1%, estimated using a target-decoy
approach67.
In vivo tumorigenicity assays and imaging. NOD scid gamma (NSG) mice were
bred and maintained under SPF conditions in the Translational Animal Research
Center at the University Medical Center Mainz. We did preliminary experiments to
determine the need for mice sample size and duration of experiment. The MDA-
MB-231 cells with stable expression of GFP and a luciferase reporter were used for
generating stable cell lines with either control shRNA or shRNA against FBXO32.
Brieﬂy, cells were counted and resuspended in a 1:1 (v/v) mixture of PBS and
Matrigel (BD Biosciences). Ten-week-old female mice were injected unilaterally
with 2 × 106 cells in 100 µl of 50:50 Matrigel/PBS into the fourth abdominal fat pad
via subcutaneous injection at the base of the nipple. Tumor growth was monitored
externally using Vernier calipers for up to 48 days. The maximum size of the tumor
that was permitted in the mice was 2700 mm3 according to ethical approval policy
of Translational Animal Research Center at the University Medical Center Mainz.
The tumor volume was calculated as follows: tumor volume (mm3)= length ×
(width)2 × 0.5. Necropsies were performed to identify macro-metastases. Primary
tumors and organs were immediately frozen in liquid nitrogen and stored at −80 °C
until use.
In vivo bioluminescence imaging of tumor-bearing mice and their organs was
performed at day 50 using an IVIS Lumina imaging system (Perkin Elmer). Brieﬂy,
mice were anesthetized with isoﬂurane and an aqueous solution of D-luciferin-K+
salt (150 mg/kg body weight) (Perkin Elmer) was injected intraperitoneally. Five
minutes after the injection, the mouse was placed onto the imaging chamber of
IVIS, and photons acquired with an integration time of 10 s were presented as
color-scaled images using IVIS Living Image Software (version 4.3.1) (Perkin
Elmer). For organ imaging, mice were euthanized after luciferin injection, and the
dissected organs were imaged as described above.
Fig. 7 FBXO32 is crucial for the maintenance of mesenchymal identity and promotes tumorigenicity and metastasis in vivo. a The levels of FBXO32 mRNA
in two human epithelial cell lines (MCF7 and MDA-MB-361) and two mesenchymal cell lines (MDA-MB-231 and BT549) were measured relative to CTCF
using RT-qPCR. bWestern blot analysis of FBXO32 in cell lines described in a. β-ACTIN acted as a loading control. c, dMigration c and invasion (d) assays
in MDA-MB-231 cells transfected with either control siRNA or siRNA against FBXO32 for 4 days. e Volcano plots showing signiﬁcantly differentially
expressed genes upon FBXO32 depletion in the MDA-MB-231 cell line. f, g Representative luciferase images of tumor-bearing mice at various time points
in the mice (f) and line graph (g) showing quantiﬁcation of tumor size growth in mice (n= 6 per condition) analyzed at various time points after mammary
fat pad injection of MDA-MB-231 cells stably expressing either control shRNA or shRNA against FBXO32 alongwith GFP and a luciferase reporter. The x-
axis represents days post-injection, and the y-axis represents the size of tumors in mm3. h, i Representative whole-body luciferase scanning (h) along with
quantiﬁcation (i) showing primary and metastatic tumors (from f to g) (n= 6 per condition). The primary tumor in the control mouse gets bigger and
become necrotic leading to a decrease in the ﬂuorescence intensity at the site of transplant. j, k Similar analysis as in h, i showing luciferase scanning image
(j), along with quantiﬁcations (k) of various organs from those mice to detect metastatic tumors. l Lung sections were collected from the mice in the above
experiment after euthanasia, and immunoﬂuorescence images were obtained using an anti-GFP antibody to detect migrated cells. m mRNA levels of key
genes deregulated upon FBXO32 depletion was validated in primary tumors obtained from the mouse used in Fig. 6i were measured relative to CTCF.
n, o H&E (n) and immunoﬂuorescence images (o) for key cytokines were measured in primary tumor obtained from the mouse used in h. Scale bar,
100 μm. Error bars represent the SEM of three independent biological replicates (n= 3). ***p< 0.001, Student’s t test. See also Supplementary Fig. 11
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Animal maintenance and experiments were performed under an approved
protocol in accordance with the animal care guidelines of Johannes Gutenberg
University.
In utero electroporation. In utero electroporation experiments were performed
essentially as previously described45. All the experimental procedures were con-
ducted in accordance with European, National, and Institutional Guidelines for
animal care. Timed-pregnant (Theiler stage 20= E12.5) C57BL/6 mice were
anesthetized with isoﬂurane (2.5% via mask, Forene®, Abbod), and carprofen (4
mg/kg body weight, Rimadyl, Pﬁzer) was administered subcutaneously as an
analgesic. After the abdominal cavity was opened, the embryos were carefully
exposed, and 1 μl of colored solution containing 1 μg of the p.SUPER-GFP shRNA
plasmid expressing shRNA against Fbxo32 or control shRNA was injected into one
of the lateral ventricles. Using specialized platinum electrodes (Nepagene CUY 650
P), the appropriate voltage was applied (50 ms, interval 950 ms, 5 pulses). After
electroporation, the uterine horns were returned to the abdominal cavity.
Cell survival assay. The cells were pre-depleted with siRNA (a pool of 4 siRNAs
targeting the same gene, SMARTpool, Dharmacon) for two days, and 40,000 cells
per 6 cm were plated and cultured for 6 days. Fresh medium along with siRNA was
added every other day. The cells were counted, or bright-ﬁeld images were
obtained, or the cells were ﬁxed with 4% PFA. To visualize the ﬁxed colonies, the
cells were stained for 10 min with a solution containing crystal violet and 10%
ethanol, and the plates were washed in water until the excess dye was washed away.
Photographs of the plates were obtained for later analysis.
Wounding migration assay. The cells depleted of FBXO32 were seeded at equal
densities, and a scratch wound was generated using a 10-μl pipette tip on conﬂuent
cell monolayers grown in six-well culture plates. The cells were then washed with
fresh medium to remove ﬂoating cells. Bright-ﬁeld images were obtained at 20x
magniﬁcation after 18 h of wounding.
Migration and invasion assays. Migration assays were performed as previously
described12. Brieﬂy, 10,000 cells were seeded in 2% FBS/DMEM (Sigma) into the
upper chamber of a 24-well Transwell migration insert (pore size 8 μm; Falcon
BD). The lower chamber was ﬁlled with 20% FBS/DMEM. After 16 h of incubation
at 37 °C, the cells in the upper chamber were removed using a cotton swab, and the
cells that had traversed the membrane were ﬁxed in 4% paraformaldehyde/PBS and
quantiﬁed by DAPI staining using a ﬂuorescence microscope and ImageJ software.
For the invasion assays, transwells were coated with 0.5 mg/ml Matrigel in serum-
free medium overnight, and 1.5 × 105 cells were used for the assays.
IP and ubiquitylation assays. HEK-293T cells were co-transfected in various
combinations with expression vectors for HA-tagged Ub, Myc-tagged CtBP1 and
Flag-tagged FBXO32 using Lipofectamine® 2000 Transfection Reagent (Thermo
scientiﬁc). For inhibition of ubiquitination pathway, UBEI/PYR-41 was added at a
ﬁnal concentration of 10 µM for 4 h. All experimental cells for ubiquitination assay
were treated with 10 µM of MG132 for 4 h prior to lysis. Cells were lysed in lysis
buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EGTA, 1.5 mM MgCl2, 1%
Glycerol, 1% Triton X-100) and centrifuged for 1 h to collect the soluble fraction.
Tagged proteins were immunoprecipitated for overnight at 4 °C with the appro-
priate antibody (5 µg/IP). Pre-blocked beads were added to the lysate and incu-
bated for 3 h at 4 °C. The bound beads were washed two times with lysis buffer and
two times with wash buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA,
0.1% Triton X-100) and analyzed by immunoblot analysis. For all IP experiments,
immunoprecipitated material was eluted with an equal volume of elution buffer
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Fig. 8 FBXO32 acts as a master regulator of EMT by governing the gene expression program underlying this process. The model showing roles of FBXO32
during EMT. The onset of EMT crucially relies on SMAD-mediated transcriptional changes, and FBXO32 is one of the ubiquitin ligases upregulated during
this process. FBXO32-mediated-K63 ubiquitination of CtBP1 leads to the nuclear retention of CtBP1 and so it can be recruited by various transcription
factors like ATF3 to assist in chromatin remodeling. This leads to alterations in the transcription of key EMT and migration promoting genes, such as Matrix
metalloproteinases (MMPs), chemokines and chemokine receptors. Such function of FBXO32 is essential for EMT in both development (e.g.,
neurogenesis) and disease (e.g., cancer metastasis) contexts, establishing this as a component of the EMT core machinery. Moreover, FBXO32-mediated
induction of cytokine secretion acts as a feed forward loop for the EMT and further enhances the epithelial to mesenchymal transition process
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and same amount of samples were loaded on gel for immunoblot analysis.To assess
ubiquitylation, 293T cells were transfected with various tagged expression vectors
in different combinations (as outlined in the manuscript ﬁgures) in the presence of
TGF-β for 4 days. Proteins lysate were precipitated with anti-Myc antibody to pull
down CtBP1 and analyzed by immunoblot using anti-HA antibody to detect Ub.
RNA sequencing data analysis. RNA-seq data were generated using Illumina
sequencing. The reads were aligned to the mouse genome (mm9) using TopHat68
(version 2.0.9) with the default options. After library size normalization using
DESeq69, expression was quantiﬁed and expressed in reads/kilobase of transcript
per million mapped reads (RPKM) using cufﬂink (version 2.1.1)68. A differential
expression analysis was performed using the DESeq package with an FDR cutoff of
0.169. Gene set enrichment analysis was performed using GSEA Preranked
module70.
Data availability. The authors declare that all the data supporting the ﬁndings of
this study are available within the article and its Supplementary Figure ﬁles or from
the corresponding author upon reasonable request. The RNA-seq data generated
during this study have been deposited in the Genbank nucleaotide database (GEO)
under accession code GSE77408. The proteomic mass spectroscopy data have been
submitted as an excel ﬁle (Supplementary Data 2). In addition to these datasets, we
had also used a number of publically available data sets (GEO accession codes:
GSE54133, GSE62146, GSE8977, GSE15471, GSE19615, GSE48408, GSE19615,
GSE48408, GSE30611, GSE95983, GSE32863, GSE31210, GSE6764, GSE62254,
GSE31210, GSE9891, GSE28814, GSE28722).
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